TCZ+PBO demonstrated mean reductions in osteitis at weeks 12 ( -5.10 ; p = 0.0022 ) and 52 ( -8.56 ; p = 0.0006 ) , while TCZ+MTX had mean reductions at weeks 2 ( -0.21 ; p < 0.05 ) and 12 ( -3.63 ; p = 0.0008 ) , but not week 52 ( -2.31 ; p = 0.9749 ) .